DUOPHARMA

DUOPHARMA BIOTECH BERHAD

Registration No: 200001021664 (524271-W)

(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 30 SEPTEMBER 2025

	INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
	CURRENT YEAR QUARTER 30/9/2025 RM'000	PRECEDING YEAR CORRESPONDING QUARTER 30/9/2024 RM'000	CURRENT YEAR TO DATE 30/9/2025 RM'000	PRECEDING YEAR CORRESPONDING PERIOD 30/9/2024 RM'000
Revenue	222,486	208,732	707,006	620,024
Cost of Sales	(131,743)	(131,942)	(439,921)	(394,025)
Gross Profit	**90,743**	**76,790**	**267,085**	**225,999**
Other operating income	192	393	288	507
Distribution costs	(33,066)	(29,437)	(95,951)	(85,173)
Administration expenses	(23,041)	(21,529)	(66,329)	(61,727)
Other operating expenses	(268)	(174)	(465)	(799)
Profit from operations	**34,560**	**26,043**	**104,628**	**78,807**
Finance income	1,527	1,445	4,349	4,530
Finance costs	(6,405)	(6,968)	(18,974)	(20,756)
Profit before taxation	**29,682**	**20,520**	**90,003**	**62,581**
Taxation	(7,111)	(4,925)	(21,588)	(15,019)
Profit after tax for the period	**22,571**	**15,595**	**68,415**	**47,562**
Other comprehensive income				
Fair value of available-for-sale financial assets	(423)	(4,225)	(503)	(12,682)
Foreign currency translation differences for foreign operations	309	346	723	980
Total other comprehensive income for the period	**22,457**	**11,716**	**68,635**	**35,860**
Profit attributable to:				
Shareholders of the Company	22,571	15,595	68,415	47,562
Minority interest	-	-	-	-
	22,571	**15,595**	**68,415**	**47,562**
Total comprehensive income attributable to:				
Shareholders of the Company	22,457	11,716	68,635	35,860
Minority interest	-	-	-	-
	22,457	**11,716**	**68,635**	**35,860**
Earnings per share (sen)				
Basic (based on weighted average)	**2.35**	**1.62**	**7.11**	**4.94**
Diluted (based on weighted average)	**2.35**	**1.62**	**7.11**	**4.94**

(The Condensed Consolidated Income Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2024 and the accompanying explanatory notes attached to the interim financial statements.)

DUOPHARMA BIOTECH BERHAD

Registration No: 200001021664 (524271-W)

(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 SEPTEMBER 2025

	UNAUDITED AS AT 30/9/2025 RM'000	AUDITED AS AT 31/12/2024 RM'000
ASSETS		
Property, Plant and Equipment	559,767	567,521
Investment property	1,050	1,050
Intangible assets	40,651	44,867
Other investments	22,162	22,665
Deferred Tax Assets	16,158	15,330
Total non-current assets	639,788	651,433
Inventories	294,408	248,548
Current Tax Assets	16,841	18,104
Trade & Other Receivables	231,130	195,203
Cash & Cash Equivalents	268,667	264,545
Total current assets	811,046	726,400
Total Assets	**1,450,834**	**1,377,833**
EQUITY		
Share Capital	432,466	432,466
Reserves	(77,870)	(78,090)
Retained earnings	389,523	354,776
Total Equity	744,119	709,152
LIABILITIES		
Borrowings	349,815	464,523
Trade & Other Payables	2,789	2,755
Deferred Tax Liability	34,686	23,418
Total non-current liabilities	387,290	490,696
Borrowings	141,179	47,995
Trade & Other Payables	174,467	129,250
Current Tax Liabilities	3,779	740
Total current liabilities	319,425	177,985
Total Liabilities	**706,715**	**668,681**
Total Equity & Liabilities	**1,450,834**	**1,377,833**
	-	-
Net assets per share (RM)	**0.77**	**0.74**

(The Condensed Consolidated Balance Sheet should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2024 and the accompanying explanatory notes attached to the interim financial statements.)

DUOPHARMA BIOTECH BERHAD

Registration No: 200001021664 (524271-W)

(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE PERIOD ENDED 30 SEPTEMBER 2025

	---------- Non-distributable	----------	----------	Distributable	
Group	Share Capital RM '000	Translation Reserve RM '000	Fair value Reserve RM '000	Retained Profit RM '000	Total RM '000
At 1 January 2025	432,466	1,143	(79,233)	354,776	709,152
Foreign currency translation differences for foreign operations	-	723	-	-	723
Net change in fair value of equity instrument designated at FVOCI	-	-	(503)	-	(503)
Profit for the period	-	-	-	68,415	68,415
Profit and total comprehensive income for the period	-	723	(503)	68,415	68,635
2024 Second Interim Dividend (2.0 sen)	-	-	-	(19,239)	(19,239)
2025 First Interim Dividend (1.5 sen)	-	-	-	(14,429)	(14,429)
At 30 September 2025	432,466	1,866	(79,736)	389,523	744,119

	---------- Non-distributable	----------	----------	Distributable	
Group	Share Capital RM '000	Translation Reserve RM '000	Fair value Reserve RM '000	Retained Profit RM '000	Total RM '000
At 1 January 2024	432,466	583	(64,991)	319,065	687,123
Foreign currency translation differences for foreign operations	-	560	-	-	560
Net change in fair value of equity instrument designated at FVOCI	-	-	(14,242)	-	(14,242)
Profit for the period	-	-	-	62,645	62,645
Profit and total comprehensive income for the period	-	560	(14,242)	62,645	48,963
2023 Second Interim Dividend (1.8 sen)	-	-	-	(17,315)	(17,315)
2024 First Interim Dividend (1.0 sen)	-	-	-	(9,619)	(9,619)
At 31 December 2024	432,466	1,143	(79,233)	354,776	709,152

(The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2024 and the accompanying explanatory notes attached to the interim financial statements.)

DUOPHARMA

DUOPHARMA BIOTECH BERHAD

Registration No: 200001021664 (524271-W)

(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENT
FOR THE PERIOD ENDED 30 SEPTEMBER 2025

	30 SEPTEMBER 2025	30 SEPTEMBER 2024
	RM '000	RM '000
Cash flows from operating activities		
Profit before taxation	90,003	62,581
Adjustments for:		
Depreciation of property, plant and equipment	30,191	30,129
Amortisation of intangible asset	3,625	3,606
Finance income from		
- Cash and cash equivalents	(4,349)	(4,530)
Impairment of inventories	9,463	6,317
Finance costs	18,974	20,756
Impairment loss/(Reversal) on trade receivables	1,041	(1,014)
Net unrealised foreign exchange loss	39	202
Gain on disposal of PPE	(10)	(395)
Operating profit before changes in working capital	148,977	117,652
Change in inventories	(52,474)	16,786
Change in receivables, deposits and prepayments	(36,967)	(64,493)
Change in payables and accruals	44,202	9,085
Cash generated from operations	103,738	79,030
Finance costs paid	(18,803)	(20,593)
Net income tax paid	(6,845)	(8,126)
Net cash from operating activities	78,090	50,311
Cash flows from investing activities		
Acquisition of property, plant and equipment	(21,894)	(14,476)
Proceeds from disposal of property, plant and equipment	10	501
Acquisition of intangible assets	(1,085)	(1,799)
Interest received from		
- Cash and cash equivalents	4,349	4,530
Net cash used in investing activities	(18,620)	(11,244)
Cash flows from financing activities		
Drawdown of borrowings	35,968	69,490
Repayment of borrowings	(57,664)	(91,603)
Dividends paid to shareholders of the Company	(33,668)	(26,934)
Payment of lease liabilities	(707)	(1,079)
Net cash used in financing activities	(56,071)	(50,126)
Net increase/(decrease) in cash and cash equivalents	3,399	(11,059)
Exchange differences on translation of financial statement of foreign	723	980
Cash and cash equivalents at 1 January	264,545	270,502
Cash and cash equivalents as at 30 September	268,667	260,423
	-	-

(I) Cash and cash equivalents comprise:

	RM '000	RM '000
Deposits placed with licensed banks	12,408	10,000
Cash and bank balances	86,946	97,694
Highly liquid investment with financial institutions	169,313	152,729
	268,667	260,423

(The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2024 and the accompanying explanatory notes attached to the interim financial statements.)

A1 Accounting Policies and Method of Computation

The interim financial statements are unaudited and have been prepared in accordance with the applicable disclosure provisions of the Listing Requirements of the Bursa Malaysia Securities Berhad, MFRS 134: *Interim Financial Reporting* and with IAS 34, *Interim Financial Reporting.*

These interim financial statements should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2024 and the explanatory notes attached to the interim financial statements.

The following MFRSs and Amendments to MFRSs applicable to the Group have been adopted with effect from 1 January 2025 :

MFRSs, interpretations and amendments effective for annual periods beginning on or after 1 January 2025

• Amendments to MFRS 121, *The Effects of Changes in Foreign Exchange Rates – Lack of Exchangeability*

The following are accounting standards, amendments and interpretations that have been issued by the Malaysian Accounting Standards Board ("MASB") but have not been adopted by the Group:

MFRSs, interpretations and amendments effective for annual periods beginning on or after 1 January 2026

• Amendments to MFRS 9, *Financial Instruments* and MFRS 7, *Financial Instruments: Disclosures – Classification and Measurement of Financial Instruments*

• Amendments that are part of Annual Improvements — Volume 11:

- Amendments to MFRS 1, *First-time Adoption of Malaysian Financial Reporting Standards*
- Amendments to MFRS 7, *Financial Instruments: Disclosures*
- Amendments to MFRS 9, *Financial Instruments*
- Amendments to MFRS 10, *Consolidated Financial Statements*
- Amendments to MFRS 107, *Statement of Cash Flows*

MFRSs, interpretations and amendments effective for annual periods beginning on or after 1 January 2027

• MFRS 18, *Presentation and Disclosure in Financial Statements*

• MFRS 19, *Subsidiaries without Public Accountability: Disclosures*

MFRSs, Interpretations and amendments effective for annual periods beginning on or after a date yet to be confirmed

• Amendments to MFRS 10, *Consolidated Financial Statements* and MFRS 128*, Investments in Associates and Joint Ventures – Sale or Contribution of Assets between an Investor and its Associate or Joint Venture*

The initial application of the above pronouncements did not have any material impact to the consolidated financial statements of the Group.

A2 Audit Report

The audited report of the Company's preceding annual financial statements was not qualified.

A3 Seasonal or Cyclical Factors

The Group's sales typically peak in the first three quarters of the calendar year with higher demand in the public health sector and will gradually taper off in the final quarter of the calendar year.

A4 Exceptional/Extraordinary Items

There were no exceptional/extraordinary items for the financial year under review.

A5 Changes in Estimates

There was no change in estimates that have a material effect in the current quarter results.

A6 Debts and Equity Securities

There were no issuance and/or repayment of debt and equity securities, share buy-backs, share cancellations, shares held as treasury shares and resale of treasury shares in the current financial year.

A7 Dividend Paid

During the current quarter, the Group paid an interim dividend of 1.5 sen per share (2024: first interim dividend of 1.0 sen per share) equivalent to RM14.43 million (2024:RM 9.62 million) in respect of financial year ending 31 December 2025.

A8 Segment Information

	Quarter Ended		Year To Date	
	30/9/2025		30/9/2025	
	RM ' 000		RM ' 000	
Sales by operating sector :-	Sales	Gross Profit	Sales	Gross Profit
Local	208,100	86,542	663,033	253,736
Export	14,386	4,201	43,973	13,349
	222,486	90,743	707,006	267,085

A9 Post Balance Sheet Events

There are no material events after the year ended up to 6 November 2025 (latest practicable date which is not earlier than 7 days from the date of issuance of this quarterly report) that have not been reflected in the financial statements for the financial period ended 30 September 2025.

A10 Changes in the Composition of the Group

There was no changes in the composition of the Group for the period under review.

ADDITIONAL INFORMATION REQUIRED BY BURSA SECURITIES LISTING REQUIREMENTS

B1 Review of Performance

	Year To Date (30/9/25) RM'000	Year To Date (30/9/24) RM'000	Variance RM'000	Variance %
Revenue	707,006	620,024	86,982	14.0
Profit before tax (PBT)	90,003	62,581	27,422	43.8
Profit after tax (PAT)	68,415	47,562	20,853	43.8

For the nine months ended 30 September 2025, the Group recorded revenue of RM707.0 million, representing a 14.0% increase compared to RM620.0 million in the corresponding period last year. The growth was primarily driven by sustained demand from both the public and private sectors across all business segments, including the additional contribution from a one-off surge in insulin supply during the first half of the year following supply normalization.

The Group’s PBT rose by 43.8% to RM90.0 million from RM62.6 million in the corresponding period last year mainly attributable to higher sales coupled with continued favourable active pharmaceutical ingredient (API) costs and foreign exchange, which collectively reinforced profitability.

B2 Comparison with the Preceding Quarter's Results

	Qtr 3 2025 (30/9/25) RM'000	Qtr 2 2025 (30/6/25) RM'000	Variance RM'000	Variance %
Revenue	222,486	221,782	704	0.3
Profit before tax (PBT)	29,682	26,584	3,098	11.7
Profit after tax (PAT)	22,571	20,204	2,367	11.7

For the third quarter ended 30 September 2025, the Group reported revenue of RM222.49 million, a marginal increase from RM221.78 million in the preceding quarter. Despite relatively stable revenue, the Group’s PBT rose by 11.7% to RM29.68 million from RM26.58 million, primarily driven by a favourable product mix as well as the continued strengthening of the Ringgit Malaysia that contributed to improved overall margins during the quarter.

B3 Prospects for the Remainder of Current Financial Year

Bank Negara Malaysia (BNM) in its Monetary Policy Statement dated 4 September 2025 highlighted that the global economy continues to expand, supported by sustained consumer spending and front-loading activities. The global growth outlook remains underpinned by positive labour market conditions, less restrictive monetary policies, and ongoing fiscal stimulus measures. Nonetheless, growth prospects are expected to remain moderated by persistent geopolitical tensions and uncertainties in global trade.

Domestically, BNM expects Malaysia’s economic activity continues to be driven by firm household spending, sustained employment growth, and the continued recovery in tourism-related sectors. The Malaysian economy expanded by 4.4% in the first half of 2025, underpinned by sustained spending and investment activities, and is on track to grow between 4% and 4.8% in 2025. In line with this outlook, the World Bank, in its latest update, has also revised Malaysia’s 2025 GDP growth forecast upward to 4.1% from 3.9%, reflecting improving momentum in domestic demand and private investment.

The National Budget 2026, tabled by the Prime Minister on 10 October 2025, further reinforces the Government’s commitment to strengthening the nation healthcare ecosystem, with an allocation of RM46.5 billion to the Ministry of Health, a 2.7 % higher than the allocation of RM45.27 billion under Budget 2025. Complementing this, the 13th Malaysia Plan (RMK-13) outlines a continued focus on enhancing healthcare capacity, advancing pharmaceutical research and manufacturing, and promoting greater self-sufficiency within the medical supply chain. Together, these initiatives form a cohesive national agenda that aligns closely with the Group’s positioning as one of Malaysia’s leading pharmaceutical manufacturers, providing opportunities for sustained growth through both public and private healthcare channels.

The following developments are also expected to augur well for the overall business performance of Duopharma Group:

a) In the second half of 2024, Duopharma (M) Sendirian Berhad and Duopharma Manufacturing (Bangi) Sdn. Bhd., both wholly-owned subsidiaries of the Company, received and accepted a total of 16 Letters of Offer (LOOs) from Pharmaniaga Logistics Sdn. Bhd. ("hereinafter referred to as the "Customer") for the supply of pharmaceutical and non-pharmaceutical products under the Ministry of Health Malaysia's Approved Products Purchase List (APPL) to offices and facilities operated by the Government of Malaysia. The total estimated value of these contracts is approximately RM665.76 million, covering 96 products.

   Subsequently, in April 2025, Duopharma Manufacturing (Bangi) Sdn. Bhd. and Duopharma HAPI Sdn. Bhd. (also a wholly-owned subsidiary of the Company), each received and accepted one additional LOO from the Customer for the supply of 1 and 3 products, valued at approximately RM1.81 million and RM16.58 million, respectively.

   Hence, the total number of products to be supplied through the Customer under the contracts is 100, with a combined estimated contract value of approximately RM684.15 million. All contracts will remain valid and binding until 31 December 2026, or such other date as may be directed by the Government of Malaysia.

b) The supply of Recombinant Human Insulin Formulations (RHI Formulations) by Duopharma Marketing Sdn. Bhd. ("DMktg") and Biocon Sdn. Bhd. ("Biocon") to the Ministry of Health Malaysia ("MOH"), pursuant to the Revised Letter of Award dated 25 April 2022 and the formal agreement for the procurement via direct negotiation for the supply of insulin medicine as a package ('Perjanjian Perolehan Secara Rundingan Terus Pembekalan Ubat Insulin Secara Pakej') between the Government of Malaysia, DMktg and Biocon that was last extended to 28 October 2025 has expired. The Group is actively pursuing the award of a new tender to supply the RHI Formulations to the MOH facilities.

The Group’s businesses continued to perform resiliently throughout the first three quarters of the year. This includes the Group’s regional operations, which recorded encouraging progress through improved market penetration and growing demand in key ASEAN markets, further strengthening its international growth platform.

Looking ahead, although global economic uncertainties arising from changes in U.S. tariff policies and persistent geopolitical tensions continue to pose external risks, the Group does not foresee any material direct impact at this stage. Nonetheless, the Group remains vigilant and closely monitors potential indirect effects on the global supply chain. On the domestic front, the recent reduction in the Overnight Policy Rate (OPR) announced by Bank Negara Malaysia in July 2025, is expected to support business sentiment and financing costs, complementing the Group’s ongoing strategic and operational initiatives.

Barring any unforeseen circumstances, the Group aims to deliver a satisfactory performance for the financial year 2025.

B4 Profit Forecast

No commentary is made on any variance between actual profit from forecast profit as it does not apply to the Group.

B5 Taxation

Details of taxation are as follows :-

	Current Year Quarter 30/9/25 RM'000	Current Year To Date 30/9/25 RM'000
Based on results for the quarter/year	(4,512)	(11,148)
Transfer (from)/to deferred tax	(2,599)	(10,440)
	(7,111)	(21,588)

The Group's tax expense is recognised in each financial quarter based on the best estimate of the expected annual effective tax rate for the full financial year.

B6 Unquoted Investments and Properties

There was no disposal of unquoted investment and/or properties during the current financial quarter.

B7 Status of Corporate Proposals

There was no corporate proposals during the current financial period.

B8 Borrowings and Debt Securities

Details of Group's borrowings are as follows :-

	As at 30 September 2025 RM'000	As at 31 December 2024 RM'000
Current - unsecured	141,179	47,995
Non-current - unsecured	349,815	464,523
Total	490,994	512,518

During the current quarter, a Sukuk tranche amounting to RM101.0 million, maturing on 29 September 2026, has been reclassified to current liabilities in accordance with its remaining maturity period of less than twelve months.

B9 Material litigation

As per the announcements made to Bursa Malaysia, on 19 February 2025, Sun Pharmaceutical Industries Limited ("the Plaintiff") commenced legal proceedings in the High Court of Malaya against Duopharma Manufacturing (Bangi) Sdn. Bhd. ("DMfgB"), a wholly owned subsidiary of the Company. The suit alleges that DMfgB's use of a specific registered trademark constitutes an infringement of the Plaintiff's own registered trademark.

At the latest case management hearing held on 30 October 2025, the Court granted an extension of time for both DMfgB and the Plantiff to file the common bundle of documents along with other pre-trial documents, such as issues to be tried, agreed facts and chronology of the case by the next case management date, which has been fixed on 24 November 2025.

The Company will announce further developments on the above matter as and when necessary.

B10 Dividend

The Directors do not recommend any interim dividend for the current quarter ended 30 September 2025. (2024:Nil)

B11 Earnings per Share

		Current year quarter 30/9/25	Current year to date 30/9/25
a)	**Basic EPS**		
	Net profit (RM'000)	22,571	68,415
	Weighted average number of ordinary shares in issue ('000)		
	-Balance b/f	961,942	961,942
		961,942	961,942
	Basic EPS (sen)	2.35	7.11
b)	**Dilutive EPS**		
	Adjusted weighted average number of ordinary shares in issue ('000)		
	-In issue during the period	961,942	961,942
		961,942	961,942
	Dilutive EPS (sen)	2.35	7.11

B12 Profit Before Tax

	Current year quarter 30/9/25 RM '000	Current year to date 30/9/25 RM '000
Operating profit is arrived at after charging / (crediting):		
Depreciation of property, plant and equipment	9,998	30,191
Finance costs	6,405	18,974
Net impairment of inventories	3,175	9,463
Net foreign exchange loss	143	210
Interest income	(1,527)	(4,349)

Other than the above, there were no other material impairment of assets nor gain or loss on derivatives for the current quarter and current year ended 30 September 2025.

B13 Authorisation for issue

The interim financial statements were authorised for issue by the Board of Directors in accordance with a resolution of the directors on 13 November 2025.

By Order of the Board

Ibrahim Hussin Salleh
Secretary
License No.: LS 0009121
SSM Practising Certificate No.: 201908001032
Kuala Lumpur
13 November 2025